Dublin, July 05, 2021 (GLOBE NEWSWIRE) -- The "Global End Stage Renal Disease Market (2021-2026) by Disease Type, Treatment Type, End-user, Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The Global End Stage Renal Disease Market is estimated to be USD 83 Bn in 2021 and is expected to reach USD 155.45 Bn by 2026, growing at a CAGR of 13.4 %.
The increasing number of patients suffering from kidney failure and the introduction of technologically advanced products, such as low maintenance dialysis equipment and artificial kidney, are the major factors expected to drive the end stage renal disease (ESRD) market. The ongoing Covid-19 pandemic has resulted in an increased demand for home dialysis across the globe.
Market Segmentation
The Global End Stage Renal Disease Market is segmented further based on Disease Type, Treatment Type, End User, and Geography.
- By Disease Type, the market is classified as Chronic Kidney Disease and End stage renal disease.
- By Treatment, the market is classified as Dialysis, Medication and kidney transplantation. Dialysis is more convenient and easier to obtain for a patient with ESRD and the whole process can be done at a dialysis center or at home.
- By Training Driving Simulator, the market is classified as Compact Simulator and Full-Scale Simulator. Amongst the two, the Compact Simulator segment is estimated to hold the highest market share.
- By End User, the market is classified as Dialysis centers, hospitals, clinics and research and academic institutes.
- By Geography, Asia Pacific is projected to lead the market.
Recent Developments
1. In February 2014, the first human clinical trials of blood purification technologies for designing Wearable Artificial Kidney 2.0 were approved by the U.S. FDA. This innovation is intended to obtain satisfactory and effective results from kidney failure patients.
Company Profiles
Some of the companies covered in this report are Nipro Corporation; Fresenius Medical Care AG & Co. KGaA; Baxter International, Inc.; Medtronic Plc; B. Braun Melsungen AG; BD; Asahi Kasei Medical Co., Ltd.; Cantel Medical; Nikkiso Co., Ltd.; JMS Co. Ltd. etc.
Competitive Quadrant
The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
Why buy this report?
- The report offers a comprehensive evaluation of the Global End Stage Renal Disease Market.
- The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
- The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
- The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
- The report also contains the competitive analysis using Competitive Quadrant, the analyst's proprietary competitive positioning tool.
Report Highlights:
- A complete analysis of the market, including parent industry
- Important market dynamics and trends
- Market segmentation
- Historical, current, and projected size of the market based on value and volume
- Market shares and strategies of key players
- Recommendations to companies for strengthening their foothold in the market
Key Topics Covered:
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Growing prevalence of diabetes and hypertension
4.2.1.2 Introduction of technologically advanced products
4.2.1.3 Increasing number of patients suffering from chronic kidney disease
4.2.2 Restraints
4.2.2.1 Risk of complications
4.2.2.2 Stringent regulatory policies for dialysis products
4.2.3 Opportunities
4.2.3.1 High Focus on technology
4.2.3.2 R&D
4.2.4 Challenges
4.2.4.1 Lack of infrastructure availability in emerging countries
4.3 Trends
5 Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis
6 Global End Stage Renal Disease Market, By Disease Type
6.1 Chronic Kidney Disease
6.2 End-Stage Renal Disease (ESRD)
7 Global End Stage Renal Disease Market, By Treatment Type
7.1 Dialysis
7.2 Medication
7.3 Kidney Transplantation
8 Global End Stage Renal Disease Market, By End Users
8.1 Dialysis Centres
8.2 Hospital & Clinics
8.3 Research and Academic Institutes
9 Global End Stage Renal Disease Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 South America
9.3.1 Brazil
9.3.2 Argentina
9.4 Europe
9.4.1 UK
9.4.2 France
9.4.3 Germany
9.4.4 Italy
9.4.5 Spain
9.4.6 Rest of Europe
9.5 Asia-Pacific
9.5.1 China
9.5.2 Japan
9.5.3 India
9.5.4 Indonesia
9.5.5 Malaysia
9.5.6 South Korea
9.5.7 Australia
9.5.8 Russia
9.5.9 Rest of APAC
9.6 Rest of the World
9.6.1 Qatar
9.6.2 Saudi Arabia
9.6.3 South Africa
9.6.4 United Arab Emirates
9.6.5 Latin America
10 Competitive Landscape
10.1 Competitive Quadrant
10.2 Market Share Analysis
10.3 Competitive Scenario
10.3.1 Mergers & Acquisitions
10.3.2 Agreement, Collaborations, & Partnerships
10.3.3 New Product Launches & Enhancements
10.3.4 Investments & Funding
11 Company Profiles
11.1 Nipro Corporation
11.2 Fresenius Medical Care AG & Co. KGaA
11.3 Baxter International, Inc.
11.4 Medtronic Plc
11.5 B. Braun Melsungen AG
11.6 BD
11.7 Asahi Kasei Medical Co., Ltd.
11.8 Cantel Medical
11.9 Nikkiso Co., Ltd.
11.10 JMS Co. Ltd.
11.11 Abbott
11.12 Amgen Inc.
11.13 AstraZeneca
11.14 Bristol-Myers Squibb Company
11.15 F. Hoffmann-La Roche Ltd
11.16 Fresenius Medical Care AG & Co.
11.17 GlaxoSmithKline PLC
11.18 Keryx Biopharmaceuticals, Inc
11.19 Kissei Pharmaceutical Co., Ltd
11.20 Novartis AG
11.21 Pfizer Inc.
11.22 Sanofi SA
11.23 Teva Pharmaceutical Industries Ltd
12 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/kr4grx